Systemic therapy for the treatment of endometrial cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109:655Y662.
   Web of Science ®Google Scholar
• National Cancer Institute. Bethesda, MD. SEER cancer stat facts: uterine cancer. [cited 2018 Oct 7]. Available from https://seer.cancer.gov/statfacts/html/corp.html
   Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45:28–36.
   PubMed Web of Science ®Google Scholar
• Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748–758.
   PubMed Web of Science ®Google Scholar
• Ali AT. Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer. 2014;24:384–393.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu H, Yang S, et al. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers. 2014;29:e21–e29.
   PubMed Web of Science ®Google Scholar
• Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141–149.
   PubMed Web of Science ®Google Scholar
• Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: cohort evidence from royal college of general practitioners’ oral contraception study. BMJ. 2010;340:c927.
   PubMed Web of Science ®Google Scholar
• Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO endometrial consensus conference working group. ESMO-ESGO-ESTRO Consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26:2–30.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–1012.
   PubMed Web of Science ®Google Scholar
• Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783–4791.
   PubMed Web of Science ®Google Scholar
• Basil JB, Goodfellow PJ, Rader JS, et al. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer. 2000;89:1758–1764.
   PubMed Web of Science ®Google Scholar
• Bilbao C, Rodriguez G, Ramirez R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer. 2006;119:563–570.
   PubMed Web of Science ®Google Scholar
• Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003;63:6–11.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22:3126–3132.
   PubMed Web of Science ®Google Scholar
• Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422–6430.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
   PubMed Web of Science ®Google Scholar
• Cosgrove CM, Tritchler DL, Cohn DE, et al. An NRG oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol. 2018;148:174–180.
   PubMed Web of Science ®Google Scholar
• Dellinger TH, Smith DD, Ouyang C, et al. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of the cancer genome atlas (TCGA). Gynecol Oncol. 2016;141:336–340.
   PubMed Web of Science ®Google Scholar
• Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer. 1987;60:2035–2041.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cavazzana A, Cosio S, et al. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res. 2009;29:1715–1720.
   PubMed Web of Science ®Google Scholar
• Guntupalli SR, Zighelboim I, Kizer NT, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol. 2012;124:31–35.
   PubMed Web of Science ®Google Scholar
• Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–823.
   PubMed Web of Science ®Google Scholar
• Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol. 1991;40:55–65.
   PubMed Web of Science ®Google Scholar
• Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S105–S143.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN Guidelines Version 1.2019. Uterine neoplasms. [cited 2018 Oct 27]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
   Google Scholar
• Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007;25:2983–2990.
   PubMed Web of Science ®Google Scholar
• RJ B, JA B, HD H, et al. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the gynecologic oncology group. Am J Clin Oncol. 1993;16:494–496.
   PubMed Web of Science ®Google Scholar
• Van Wijk FH, Aapro MS, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC gynaecological cancer group. Ann Oncol. 2003;14:441–448.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902–3908.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:2159–2166.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Papadimitriou CA, Georgoulias V, et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study. Gynecol Oncol. 2000;78:52–57.
   PubMed Web of Science ®Google Scholar
• Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study. J Clin Oncol. 2001;19:4048–4053.
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Pisano C, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian trials in ovarian cancer and gynecologic malignancies) group. Br J Cancer. 2007;96:1639–1643.
   PubMed Web of Science ®Google Scholar
• Vale CL, Tierney J, Bull S, et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 2012;8:CD003915.
   PubMedGoogle Scholar
• Miller D, Filiaci V, Fleming G, et al. Late-breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;125:771.
   Web of Science ®Google Scholar
• Tabata T, Tanida K, Umekawa T, et al. Weekly low-dose paclitaxel and carboplatin therapy in gynecological cancer patients with venous thrombosis. Anticancer Res. 2008;28:3971–3975.
   PubMed Web of Science ®Google Scholar
• Secord AA, Havrilesky LJ, Carney ME, et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol. 2007;12:31–36.
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study. Gynecol Oncol. 2007;106:16–22.
   PubMed Web of Science ®Google Scholar
• JT T, JA B, PJ D, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 1994;12:1408–1414.
   PubMed Web of Science ®Google Scholar
• Weber B, Mayer F, Bougnoux P, et al. What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results. Proc Am Soc Clin Oncol. 2003;22:453. Abstract 1819.
   Google Scholar
• Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a gynecologic oncology group study. Ann Oncol. 2004;15:1173–1178.
   PubMed Web of Science ®Google Scholar
• Long HR 3rd, RA N, KC P, et al. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecol Oncol. 2006;100:501‐5.
   Web of Science ®Google Scholar
• Nomura H, Aoki D, Takahashi F, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese gynecologic oncology group study (JGOG2041). Ann Oncol. 2011;22:636‐42.
   PubMed Web of Science ®Google Scholar
• Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:1625–1634.
   PubMedGoogle Scholar
• Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95:266–271.
   PubMed Web of Science ®Google Scholar
• Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese gynecologic oncology group study. Gynecol Oncol. 2008;108:226–233.
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2006;24:36–44.
   PubMed Web of Science ®Google Scholar
• Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist. 2016;21:1250–1259.
   PubMed Web of Science ®Google Scholar
• Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422–2431.
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019:JCO1801575. DOI: 10.1200/JCO.18.01575
   Web of Science ®Google Scholar
• Qu XM, Velker VM, Leung E, et al. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. Gynecol Oncol. 2018;149:283–290.
   PubMed Web of Science ®Google Scholar
• De Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–309.
   PubMed Web of Science ®Google Scholar
• Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a gynecologic oncology group study. Gynecol Oncol. 1990;36:166–171.
   PubMed Web of Science ®Google Scholar
• Kuoppala T, Mäenpää J, Tomas E, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol. 2008;110:190–195.
   PubMed Web of Science ®Google Scholar
• ENGOT-EN2-DGCG/EORTC-55102: A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. ClinicalTrials.gov identifier (NCT number): NCT01244789. [cited 2018 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01244789
   Google Scholar
• Gibbons S, Martinez A, Schray M, et al. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1991;21:1019–1025.
   PubMed Web of Science ®Google Scholar
• Secord AA, Geller MA, Broadwater G, et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol. 2013;128:65–70.
   PubMed Web of Science ®Google Scholar
• Lum MM, Belnap TW, Frandsen J, et al. Survival analysis of cancer patients with FIGO stage IIIA endometrial cancer. Am J Clin Oncol. 2015;38:283–288.
   PubMed Web of Science ®Google Scholar
• Lester-Coll NH, Park HS, Rutter CE, et al. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the national cancer data base. Gynecol Oncol. 2016;142:54–61.
   PubMed Web of Science ®Google Scholar
• Matei D, Filiaci VL, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380:2317–2326.
   PubMed Web of Science ®Google Scholar
• Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2007;106:325–333.
   PubMed Web of Science ®Google Scholar
• Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17:964–978.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group. J Clin Oncol. 1999;17:1736–1744.
   PubMed Web of Science ®Google Scholar
• Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92:4–9.
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92:10–14.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001;19:364–367.
   PubMed Web of Science ®Google Scholar
• Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2000;78:212–216.
   PubMed Web of Science ®Google Scholar
• Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the national cancer institute of Canada clinical trials group. Int J Gynecol Cancer. 2004;14:650–658.
   PubMed Web of Science ®Google Scholar
• Tadakawa M, Takeda T, Li B, et al. The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1alpha signaling pathway in ELT-3 cell. Mol Cell Endocrinol. 2015;399:1–8.
   PubMed Web of Science ®Google Scholar
• Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: Systematic review and meta-analysis. Gynecol Oncol. 2017;147:167–180.
   PubMed Web of Science ®Google Scholar
• Makker V, Green AK, Wenham RM, et al. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4:19.
   PubMedGoogle Scholar
• Rose PG, Ali S, Moslemi-Kebria M, et al. Carboplatin, and Bevacizumab in advanced and recurrent endometrial carcinoma. Int J Gynecol Cancer. 2017 Mar;27:452–458.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Colombo N, et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: the MITO END-2 trial. J Clin Oncol. 2015;33. abstr 5502.
   PubMed Web of Science ®Google Scholar
• Husseinzadeh N, Husseinzadeh HD. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review. Gynecol Oncol. 2014;133:375–381.
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC clinical trials group. J Clin Oncol. 2011;29:3278–3285.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33:930–936.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018;150:274–281.
   PubMed Web of Science ®Google Scholar
• Mo Z, Liu J, Zhang Q, et al. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett. 2016;12:944–950.
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PDl1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomark Prev. 2014;23:2965–2970.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413.
   PubMed Web of Science ®Google Scholar
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28). ClinicalTrials.gov identifier (NCT number): NCT02054806. [cited 2018 Dec 31]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02054806
   Google Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death Ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35:2535–2541.
   PubMed Web of Science ®Google Scholar
• ENGOT-EN7/MaNGO/AtTEnd. Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. ClinicalTrials.gov identifier (NCT number): NCT03603184. [cited 2018 Dec 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT03603184
   Google Scholar
• Reinbolt R, Hays J. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol. 2013;3:237.
   PubMedGoogle Scholar
• Konecny GE, Santos L, Winterhoff B, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100:89–95.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:15–20.
   PubMed Web of Science ®Google Scholar
• Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137–146.
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial Carcinoma. Lancet. 2000;355:1404–1411.
   PubMed Web of Science ®Google Scholar
• Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92:744–751.
   PubMed Web of Science ®Google Scholar
• Wortman BG, Bosse T, Nout RA, et al. PORTEC study group. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol. 2018;151:69–75.
   PubMed Web of Science ®Google Scholar